All IndicationsInfectious DiseasePhase 3Phase 3Phase 3Phase 3Phase 2Phase 2
🦠
Hepatitis B
3
Companies
6
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
GSK
GSK plc
Combined Hepatitis A and B vaccine
DVAX
Dynavax Technologies Corporation
Engerix-B
DVAX
Dynavax Technologies Corporation
HEPLISAV
SNY
Sanofi
DTaP-IPV//PRP~T combined
GSK
GSK plc
Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
GSK
GSK plc
Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| GSK GSK plc | Combined Hepatitis A and B vaccine | Phase 3 | — | — | — |
| DVAX Dynavax Technologies Corporation | Engerix-B | Phase 3 | — | — | — |
| DVAX Dynavax Technologies Corporation | HEPLISAV | Phase 3 | — | — | — |
| SNY Sanofi | DTaP-IPV//PRP~T combined | Phase 3 | — | — | — |
| GSK GSK plc | Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A. | Phase 2 | — | — | — |
| GSK GSK plc | Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
4
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.